Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
äŒæ¥ã³ãŒãCERT
äŒç€ŸåCertara Inc
äžå Žæ¥Dec 11, 2020
æé«çµå¶è²¬ä»»è
ãCEOãFeehery (William F)
åŸæ¥å¡æ°1487
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Dec 11
æ¬ç€Ÿæåšå°4 Radnor Corporate Center, Suite 350
éœåžRADNOR
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·19087
é»è©±çªå·14152378272
ãŠã§ããµã€ãhttps://www.certara.com/
äŒæ¥ã³ãŒãCERT
äžå Žæ¥Dec 11, 2020
æé«çµå¶è²¬ä»»è
ãCEOãFeehery (William F)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã